Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …

Over the past two decades, bile acids (BAs) have become established as important
signaling molecules that enable fine-tuned inter-tissue communication from the liver, their …

Farnesoid X receptor (FXR) is a bile acid activated nuclear receptor (BAR) and is mainly
expressed in the liver and intestine. Upon ligand binding, FXR regulates key genes involved …

Background & Aims EDP-305 is an oral farnesoid X receptor (FXR) agonist under
development for treating nonalcoholic steatohepatitis (NASH). The efficacy, safety, and …

Cholestasis is a condition characterized by the abnormal production or excretion of bile, and
it can be induced by a variety of causes, the factors of which are extremely complex …

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed
in liver and intestine, regulates the expression of genes involved in cholesterol and bile acid …

Chronic cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary
sclerosing cholangitis (PSC), are associated with bile stasis and gradually progress to …

Up to 40% of patients with primary biliary cholangitis have an incomplete response to first-
line treatment with ursodeoxycholic acid. Obeticholic acid was approved by the US Food …

Liver fibrosis plays a critical role in the evolution of most chronic liver diseases and is
characterized by a buildup of extracellular matrix, which can progress to cirrhosis …